

Remarks

Claims 1-4 and 7-9 are pending. Claims 1, 3 and 7 have been amended.

Rejections under 35 USC 112

Claims 1 and 3 have been rejected as failing to comply with the written description requirement.

In response, Applicants have amended claims 1 and 3 to specify that that the claimed polypeptide fragments bind to B4 integrin. Accordingly, the claims now recite not only that the polypeptide fragments comprise the B4 integrin binding sequence, but that the fragments bind to B4 integrin. Applicants submit the claims now recite sufficient identifying characteristics such that the written description requirement is clearly met. The Examiner is respectfully requested to remove the stated rejection.

Claim 7 has been rejected to recite a peptide of 10 amino acids. Applicants point out, and as the Examiner has acknowledged, original claim 7 recited a peptide of about 10 amino acids comprising SEQ ID NO:61. Thus, Applicants submit that there is an adequate basis in the specification as filed to support the present amendment to claim 7.

Conclusion


Based upon the amendments and arguments presented herein, Applicant believes the present application is now in condition for allowance and respectfully requests the Examiner to allow all the claims.

Applicants enclose herewith a Request for Continued Examination and a check for the required fee. It is believed no additional fee is due with this response. If any fee is due, the Examiner is authorized to charge it (or credit any overpayment) to Deposit Account No. 08-2442.

Respectfully submitted,

HODGSON RUSS LLP

By


John D. Lopinski, Reg. No. 50,846

One M&T Plaza, Suite 2000
Buffalo, New York 14203
(716) 848-1430
Dated: February 6, 2007